Chris De Savi

Discovery, Synthesis, and <i>in Vivo</i> Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase

Andrew Mortlock, Kevin M. Foote, Nicola M. Heron et al. · Journal of Medicinal Chemistry · 2007 · 274 citations · Full text

Medicine, Oncology, Pharmacology +13

AZD9496: An Oral Estrogen Receptor Inhibitor That Blocks the Growth of ER-Positive and <i>ESR1</i> -Mutant Breast Tumors in Preclinical Models

Hazel M. Weir, Robert H. Bradbury, Mandy Lawson et al. · Cancer Research · 2016 · 174 citations

Medicine, Oncology, Pharmacology +16

Optimization of a Novel Binding Motif to (<i>E</i>)-3-(3,5-Difluoro-4-((1<i>R</i>,3<i>R</i>)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1<i>H</i>-pyrido[3,4-<i>b</i>]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Chris De Savi, Robert H. Bradbury, Alfred A. Rabow et al. · Journal of Medicinal Chemistry · 2015 · 160 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung Cancer

Meredith S. Eno, Jason D. Brubaker, John E. Campbell et al. · Journal of Medicinal Chemistry · 2022 · 160 citations · Full text

Medicine, Oncology, Pharmacology +14

Total Synthesis of the Microtubule-Stabilizing Agent (−)-Laulimalide

Ian Paterson, Chris De Savi, Matthew T. Tudge · Organic Letters · 2001 · 116 citations

Medicine, Medicinal Chemistry, Pharmacology +12